Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496336 | 1.00 | CDC7 (0.46) | CDC7CCNE1CDK2DBF4IKBKB | |
| SCHEMBL17748308 | 0.86 | NNMT (0.44) | CDC7CCNE1CDK2DBF4IKBKB | |
| SCHEMBL30592770 | 0.81 | MAPT (0.47) | POLBTSHRCA1CA2ALDH1A1 | |
| SCHEMBL1111686 | 0.81 | MAPT (0.47) | POLBTSHRCA1CA2ALDH1A1 | |
| SCHEMBL336307 | 0.81 | BCHE (0.39) | CDC7CCNE1CDK2DBF4POLB | |
| SCHEMBL30748963 | 0.80 | ALOX5 (0.35) | CDC7CCNE1CDK2DBF4SIRT6 | |
| SCHEMBL27805414 | 0.80 | PARP10 (0.43) | IKBKBTSHRPARP10ALDH1A1KMT2A | |
| SCHEMBL20702390 | 0.80 | IKBKB (0.44) | CDC7CCNE1CDK2DBF4IKBKB | |
| Hydrochloric Acid SCHEMBL17674838 | 0.79 | MAPT (0.46) | POLBTSHRCA1CA2ALDH1A1 | |
| SCHEMBL31214279 | 0.79 | NPSR1 (0.48) | TSHRCA1CA2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | claimed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | claimed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3383493-A1 | C5-C6-CARBOCYCLIC FUSED IMINOTHIADIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6902902-B2 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| US-6291674-B2 | REACTING GLYOXAL DERIVATIVE AND AMINOIMIDATE DERIVATIVE TO FORM 3-ALKOXY/ARYLOXY-5-(ALKYL/ARYL)PYRAZINE-2-CARBOXAMIDE; REACTING WITH ALKALI METAL HYPOHALITE TO FORM 3-ALKOXY/ARYLOXY-5-(ALKYL/ARYL)PYRAZINE-2-AMINE | LONZA AG (CH) | 2001-09-18 | — | — | US | disclosed |
| US-20010012894-A1 | Process for preparing alkoxypyrazine derivatives | FUCHS RUDOLF (CH) | 2001-08-09 | — | — | US | disclosed |
| US-6235905-B1 | REACTING A GLYOXAL DERIVATIVE WITH A AMINOACETIMIDATE | LONZA AG (CH) | 2001-05-22 | — | — | US | disclosed |
| US-6066736-A | Process for preparing alkoxypyrazine derivatives | LONZA AG (CH) | 2000-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | CDC7 4281/4885CCNE1 4435/4885CDK2 1744/4885 |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | CDC7 4281/4885CCNE1 4435/4885CDK2 1744/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | CDC7 3095/4885CCNE1 1701/4885CDK2 1905/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | CDC7 3917/4885CCNE1 2021/4885CDK2 2625/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | CDC7 3902/4885CCNE1 2047/4885CDK2 2667/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | CDC7 4233/4885CCNE1 2112/4885CDK2 2775/4885 |
| US-20010012894-A1 | Process for preparing alkoxypyrazine derivatives | CYP3A5, GMDS, CYP3A43 | CDC7 2832/4885CCNE1 559/4885CDK2 654/4885 |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | CDC7 2541/4885CCNE1 854/4885CDK2 794/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | CDC7 3906/4885CCNE1 2073/4885CDK2 2647/4885 |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | CDC7 4281/4885CCNE1 4435/4885CDK2 1744/4885 |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | CDC7 4281/4885CCNE1 4435/4885CDK2 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.